(dailyRx News) Stem cell transplants are potentially curative treatments for blood cancer patients. But a common side effect of this procedure, called graft-versus-host disease, can be very serious, even deadly.
A small trial showed that Zolinza (vorinostat) halved the incidence of graft-versus-host disease following stem cell transplants in patients with blood cancers.
This study found that when combined with other standard medications given with a transplant, Zolinza was safe for patients whose transplant used stem cells from close relatives.
Read more from RxWiki HERE.
Posted in Industry News